Quantitative Systematic Strategies LLC purchased a new stake in shares of Raptor Pharmaceutical Corp. (NASDAQ:RPTP) during the second quarter, Holdings Channel reports. The firm purchased 92,474 shares of the company’s stock, valued at approximately $495,000.
Separately, Jacobs Levy Equity Management Inc. purchased a new position in shares of Raptor Pharmaceutical Corp. during the first quarter valued at about $771,000. Hedge funds and other institutional investors own 54.91% of the company’s stock.
Shares of Raptor Pharmaceutical Corp. (NASDAQ:RPTP) remained flat at $8.98 during midday trading on Friday. The stock had a trading volume of 2,482,326 shares. The company’s market capitalization is $766.05 million. The company has a 50-day moving average price of $8.48 and a 200-day moving average price of $6.25. Raptor Pharmaceutical Corp. has a 12-month low of $2.94 and a 12-month high of $9.01.
Raptor Pharmaceutical Corp. (NASDAQ:RPTP) last issued its quarterly earnings results on Thursday, August 4th. The company reported ($0.16) earnings per share (EPS) for the quarter, beating the Thomson Reuters’ consensus estimate of ($0.18) by $0.02. Raptor Pharmaceutical Corp. had a negative return on equity of 66.67% and a negative net margin of 79.29%. The company had revenue of $32.05 million for the quarter, compared to analyst estimates of $28.52 million. During the same quarter last year, the company posted ($0.17) EPS. The company’s revenue for the quarter was up 37.4% compared to the same quarter last year. On average, equities analysts anticipate that Raptor Pharmaceutical Corp. will post ($0.90) EPS for the current fiscal year.
RPTP has been the topic of several research reports. Citigroup Inc. lowered Raptor Pharmaceutical Corp. from a “buy” rating to a “neutral” rating and upped their price target for the company from $6.00 to $8.00 in a research note on Monday, August 8th. Zacks Investment Research raised Raptor Pharmaceutical Corp. from a “hold” rating to a “buy” rating and set a $7.50 target price on the stock in a research note on Thursday, August 11th. Cowen and Company reissued a “buy” rating and issued a $8.00 target price on shares of Raptor Pharmaceutical Corp. in a research note on Friday, August 19th. FBR & Co reissued a “hold” rating and issued a $10.00 target price on shares of Raptor Pharmaceutical Corp. in a research note on Tuesday, August 23rd. Finally, Wedbush reissued a “neutral” rating and issued a $4.00 target price (down previously from $9.00) on shares of Raptor Pharmaceutical Corp. in a research note on Monday, September 12th. Six analysts have rated the stock with a hold rating and two have assigned a buy rating to the company. Raptor Pharmaceutical Corp. presently has an average rating of “Hold” and an average target price of $8.25.
Raptor Pharmaceutical Corp. Company Profile
Raptor Pharmaceutical Corp. (Raptor) is a biopharmaceutical company. The Company is focused on developing and commercializing transformative treatments for people affected by diseases. Its product, PROCYSBI (cysteamine bitartrate) is a delayed-release capsules for the management of nephropathic cystinosis in adults and children of over six years.